Pharmacy Benefit Management

Florida PBM Lawsuit: The Missing Audit Trail Behind Drug-Benefit Savings

Florida’s PBM lawsuit against Prime Therapeutics and Express Scripts raises a larger oversight question: who controls pharmacy reimbursement, and can plan sponsors trace reported savings to net plan economics?

💡

TL;DR:
Florida alleges Prime Therapeutics and Express Scripts coordinated pharmacy reimbursement. The deeper issue for plan sponsors is whether reported PBM savings can be traced to actual plan value.

What You Need to Know

The change: Prime and Express Scripts announced a collaboration in December 2019 under which Express Scripts would provide Prime services related to retail pharmacy networks and pharmaceutical-manufacturer contracts. Prime Therapeutics and Express Scripts collaboration announcement
Who is affected: Pharmacies are directly implicated by Florida’s reimbursement allegations. Plan sponsors, employers, benefits fiduciaries, and compliance leaders also need to understand how PBM contracting decisions affect net plan economics.
Why it matters: Lower pharmacy reimbursement does not by itself prove either consumer harm or consumer savings. The unresolved questions include who controlled the reimbursement decision and where the resulting value went.
What to do first: Map who performs each material PBM function and whether the organization can trace reported savings to actual plan costs.
Key date: Florida filed its lawsuit on August 27, 2026. Florida Attorney General announcement

The signal is public. The implications are not.

Members receive deeper analysis and early warnings inside the PolicyEdge AI Intelligence Terminal.

Upgrade to Founding Member

CSBS AI Supervisory Framework visual with layered data paths converging through a central review structure.

CSBS AI Supervisory Framework: What State Examiners May Ask

The CSBS AI Supervisory Framework gives state examiners a clearer approach to AI oversight. See what it covers, how it differs from federal model-risk guidance, and what financial institutions should review.

DOJ AI regulation by prosecution visualized as data signals meeting a fixed legal boundary in a dark policy grid.

DOJ AI Regulation by Prosecution: What Blanche’s Line Means

Attorney General Todd Blanche says DOJ will not pursue “regulation by prosecution” against AI companies absent a statutory violation. Existing employment and consumer-protection laws can still apply when AI is involved.

ChatGPT Health and HIPAA visualized as health-data streams crossing regulatory boundaries into consumer AI.

ChatGPT Health and HIPAA: What Changes When Health Data Moves to Consumer AI

ChatGPT Health can receive patient-directed health data outside HIPAA’s framework. Here’s what HHS, FTC rules, and state privacy laws mean for governance teams.

AI securities litigation visual with converging signal lines moving through layered governance controls.

AI Securities Litigation: What H1 2026 Data Actually Shows

AI-related cases were a minority of H1 2026 securities filings but accounted for 73% of two major market-loss measures. Here’s what the numbers mean for boards, GCs, disclosure teams, IR, and AI leaders.